OTCMKTS:CLABF Core One Labs (CLABF) Stock Price, News & Analysis → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free CLABF Stock Alerts $0.13 0.00 (0.00%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.13▼$0.1752-Week Range$0.12▼$0.50Volume1,559 shsAverage Volume4,766 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Core One Labs alerts: Email Address Ad Weiss RatingsNvidia is now part of $3 Trillion Market Cap ClubA small handful of Nvidia’s partners could see their own stocks surge upwards. They’re virtually unknown right now, but that won’t be the case much longer.Click here to find out who they are today. About Core One Labs Stock (OTCMKTS:CLABF)Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.Read More CLABF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLABF Stock News HeadlinesMay 27, 2024 | msn.comKlipsch Flexus Core 100 Review: Great Sound from Single BarApril 24, 2024 | seekingalpha.comCLB Core Laboratories Inc.February 23, 2024 | finance.yahoo.comCore One Labs Inc. (CLABF)February 1, 2024 | morningstar.comCore One Labs IncDecember 8, 2023 | finance.yahoo.comCore One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International MarketDecember 1, 2023 | finance.yahoo.comCore One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment MethodsOctober 9, 2023 | msn.comHalliburton And Core Laboratories Collaborate To Accelerate Digital Rock Data SolutionsSeptember 1, 2023 | msn.comNew KU core laboratory enhances research for infectious diseaseAugust 18, 2023 | finanznachrichten.deÜbersicht Suchergebnisse zum Thema CORE ONE LABS INCAugust 16, 2023 | msn.comCore Laboratories: 'Spooked The Herd' In June, Things Might Be Looking UpAugust 4, 2023 | finance.yahoo.comCore One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's DiseaseAugust 1, 2023 | finance.yahoo.comCore One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom BiomassJuly 28, 2023 | benzinga.comCore One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's DiseaseJuly 28, 2023 | finance.yahoo.comCore One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s DiseaseJuly 24, 2023 | benzinga.comCore One Labs Enters Into LOI For First Sale Of Its Psychedelic CompoundsJuly 21, 2023 | finanznachrichten.deCore One Labs Inc.: Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic CompoundsJuly 21, 2023 | finance.yahoo.comCore One Labs Enters into Letter of Intent for First Sale of Its Psychedelic CompoundsJuly 11, 2023 | finance.yahoo.comCore One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic PsilocybinJuly 7, 2023 | finanznachrichten.deCore One Labs Inc.: Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production MethodJuly 7, 2023 | finance.yahoo.comCore One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production MethodMay 5, 2023 | finanznachrichten.deCore One Labs Inc.: Core One in Talks with Multiple Companies to Supply PsilocybinMay 1, 2023 | finance.yahoo.comCore One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding PharmacyApril 24, 2023 | msn.comCore One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of PsilocinApril 21, 2023 | finanznachrichten.deCore One Labs Inc.: Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing FacilityApril 21, 2023 | finance.yahoo.comCore One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing FacilitySee More Headlines Receive CLABF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Core One Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:CLABF CUSIPN/A CIK1640152 Webcore1labs.com Phone(866) 452-6731FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Joel Shacker (Age 33)CEO & Director Comp: $178.23kMr. Geoffrey Balderson (Age 46)CFO, Secretary & Director Comp: $30.04kDr. Santiago FerroChief Medical Officer & DirectorMr. Brad Paul Eckenweiler (Age 70)Founder & Advisor Mr. Jan Burian Ph.D.Chief Technical OfficerDr. Elizabeth MatthewsHead of Scientific & Regulatory AffairsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors CLABF Stock Analysis - Frequently Asked Questions How have CLABF shares performed in 2024? Core One Labs' stock was trading at $0.2389 at the beginning of the year. Since then, CLABF stock has decreased by 45.5% and is now trading at $0.1303. View the best growth stocks for 2024 here. Are investors shorting Core One Labs? Core One Labs saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,000 shares, a decline of 52.4% from the April 30th total of 4,200 shares. Based on an average daily volume of 11,900 shares, the short-interest ratio is currently 0.2 days. View Core One Labs' Short Interest. How do I buy shares of Core One Labs? Shares of CLABF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CLABF) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored$9 AI Model with 90% Win Rate?What if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Core One Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Core One Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.